IPO Plus

89.03

+1.16 +1.32%

As of 05 Aug 2026 · delayed

NSE Listed · Healthcare

Bal Pharma Limited (BALPHARMA)

Volume: 14,562Avg Vol 1W: 14,948Avg Vol 1M: 62,00152W Range:6098.85
Key Ratios
Checked 2h ago
Market Cap₹142 Cr
Current Price₹89.03
Previous Close₹87.87
High / Low (52w)₹98.85 / ₹60
Volume14,562
Avg Vol (1W)14,948
Avg Vol (1M)62,001
Stock P/E22.54
Book Value₹51.71
Dividend Yield1.37%
ROE7.92%
ROA3.66%
Revenue (TTM)
Revenue Growth
Profit Margin
Total Debt₹31 Cr
Shares Outstanding2 Cr
Face Value₹10
EPS (TTM)₹3.95
P/B1.72
Debt / Equity201.2
50 DMA₹85.9
200 DMA₹77.67
Day change+1.32%
Price Chart
89.03 7.68% · 1Y
107605.4L
2025-08-05
2026-08-05

20-day avg volume: 66K shares

Cons
  • High debt relative to equity.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹74 Cr₹74 Cr₹73 Cr₹82 Cr₹66 Cr₹74 Cr₹88 Cr₹84 Cr
EBITDA₹5 Cr₹5 Cr₹6 Cr₹7 Cr₹4 Cr₹5 Cr₹7 Cr₹7 Cr
Net Profit₹0 Cr₹1 Cr₹0 Cr₹5 Cr₹0 Cr₹1 Cr₹2 Cr₹4 Cr
EPS
Profit & Loss (Annual)
MetricSept 2024Dec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹75 Cr₹73 Cr₹82 Cr₹305 Cr₹66 Cr₹74 Cr₹87 Cr₹84 Cr
EBITDA₹6 Cr₹6 Cr₹7 Cr₹22 Cr₹4 Cr₹5 Cr₹7 Cr₹7 Cr
Net Profit₹1 Cr₹1 Cr₹6 Cr₹7 Cr₹0 Cr₹1 Cr₹2 Cr₹4 Cr
EPS4.54
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹260 Cr₹261 Cr₹238 Cr₹240 Cr₹261 Cr₹313 Cr₹320 Cr₹336 Cr
Total Liabilities₹200 Cr₹201 Cr₹193 Cr₹187 Cr₹202 Cr₹249 Cr₹248 Cr₹258 Cr
Equity₹60 Cr₹60 Cr₹45 Cr₹53 Cr₹58 Cr₹64 Cr₹72 Cr₹77 Cr
Total Debt
Cash Flow
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹2 Cr₹10 Cr₹23 Cr₹22 Cr₹28 Cr₹-1 Cr₹27 Cr₹22 Cr
Investing₹-4 Cr₹-8 Cr₹-5 Cr₹-6 Cr₹-9 Cr₹-22 Cr₹-19 Cr₹-15 Cr
Financing₹4 Cr₹0 Cr₹-20 Cr₹-17 Cr₹-17 Cr₹24 Cr₹-1 Cr₹-8 Cr
Free Cash Flow₹2 Cr₹10 Cr₹23 Cr₹22 Cr₹28 Cr₹-1 Cr₹27 Cr₹22 Cr
Shareholding
Promoter 65.28% Institutions 0% Public 34.72%
About Bal Pharma Limited

Healthcare · Drug Manufacturers - Specialty & Generic

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.

www.balpharma.com
Efficiency & Working Capital
ROCE9.4%
Interest Coverage1.3
Dividend Payout
Debtor Days111 d
Inventory Days124 d
Payable Days98 d
Cash Conversion Cycle137 d
Working Capital Days235 d
Shareholding Details

As of 2026-06-30

Promoter50.9%
FII0.1%
DII0%
Institutions0.1%
Public49%
Promoter Pledge0%
No. of Shareholders14,974
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters51.6%51.2%51.2%51.2%50.9%50.9%50.9%50.9%50.9%50.9%50.9%50.9%
FIIs0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.2%0.2%0.1%0.1%0.1%
DIIs0%0%0%0%0%0%0%0%0%0%0%0%
Public48.3%48.6%48.6%48.6%49%49%49%49%48.9%49%49%49%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders15,52915,06014,77215,01416,00715,66715,72315,82615,77415,52015,21414,974
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Shailesh SiroyaShareholding of Promoter and Promoter Group17.2%27,45,459
Micro Labs LimitedShareholding of Promoter and Promoter Group12.6%20,11,736
Anita SiroyaShareholding of Promoter and Promoter Group6.6%10,49,220
Prakash Chandra JainPublic Shareholding3.4%5,48,311
Ram Keshav MurthyPublic Shareholding3.3%5,27,600
Anand SuranaShareholding of Promoter and Promoter Group3.3%5,25,686
Chandraprakash Dheerajmal SiroyaShareholding of Promoter and Promoter Group3.1%4,86,420
Dilip SuranaShareholding of Promoter and Promoter Group3%4,74,994
Naresh D PPublic Shareholding1.9%3,00,000
Shreya MardiaPublic Shareholding1.9%3,00,000
Asha Tapidas DodhiaPublic Shareholding1.8%2,93,247
Archana SuranaShareholding of Promoter and Promoter Group1.8%2,84,996
Gautam Chand MehtaPublic Shareholding1.2%1,84,966
Monica SuranaShareholding of Promoter and Promoter Group1.1%1,79,909
Dilip Surana (huf)Shareholding of Promoter and Promoter Group1.1%1,69,995
Anita Chandraprakash SiroyaShareholding of Promoter and Promoter Group0.8%1,22,687
Jivi Dheerajmal SiroyaShareholding of Promoter and Promoter Group0.3%46,080
Shrenik SiroyaShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Shailesh SiroyaED / MD / Promoter2025
Himesh VirupakshayaE D & Wholetime Director2025
H S VenkateshIndependent Non Exe. Director2025
Nicola NeeladriIndependent Non Exe. Director2025
Jatish ShethIndependent Non Exe. Director2025
Ravindrakumar KothariIndependent Non Exe. Director2025
Abdul BasithCompany Sec. & Compli. Officer2025
Bheekamchand MukeshAdditional Director2025
Segments — Product
SegmentRevenueShare
manufacturing and marketing of phar₹0 Cr
Segments — Geography
RegionRevenueShare
India₹105 Cr46.5%
Other than India₹121 Cr53.5%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹10251616
Corporate Actions
TypeDateValueRemark
dividend2025-09-18₹1.2 (12%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025100348
2025000000
2025000314
Insider / Designated-Person Trades

5 recent disclosure(s)

SHAILESH SIROYAAcquisition · 7,50,000
MICRO LABS LIMITED RevisedAcquisition · 3,00,900
MICRO LABS LIMITED RevisedAcquisition · 3,00,900
MICRO LABS LIMITEDAcquisition · 4,00,000
MICRO LABS LIMITEDAcquisition · 3,00,900
Substantial Acquisitions (SAST)

3 disclosure(s)

Pref. Allotment13/04/2022 · 7,50,000
Market23/11/2021 · 4,00,000
Market27/08/2021 · 3,00,900
Company Information
Incorporated1987
AuditorSSJNB & Co
Investor Email[email protected]
🌐 www.balpharma.com

📍 21 & 22 Bommasandra Indl Area, Hosur Road, Bangalore, Karnataka, 560092

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search

Telegram App